Literature DB >> 16801447

Prospective determination of plasma imipenem concentrations in critically ill children.

Eric Giannoni1, Philippe Moreillon, Jacques Cotting, Adrien Moessinger, Jacques Bille, Laurent Décosterd, Giorgio Zanetti, Paul Majcherczyk, Denis Bugnon.   

Abstract

Plasma imipenem concentrations were measured in 19 critically ill children (median age, 0.8 year; range, 0.02 to 12.9 years). Wide interindividual variations (2 to 4x at peak and >10x at trough concentrations) resulted in unpredictable plasma levels in several children. To avoid subtherapeutic drug levels, we recommend treatment with at least 100 mg/kg of body weight/day of imipenem-cilastatin for critically ill children requiring such therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801447      PMCID： PMC1489785          DOI： 10.1128/AAC.01149-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Antimicrobial therapy for infants and children: guidelines for the inpatient and outpatient practice of pediatriac infectious diseases.

Authors:  N K Henry; J L Hoecker; K H Rhodes
Journal:  Mayo Clin Proc       Date:  2000-01       Impact factor: 7.616

Review 2.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

3.  Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development.

Authors:  A Prader; R H Largo; L Molinari; C Issler
Journal:  Helv Paediatr Acta Suppl       Date:  1989-06

4.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

5.  Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life.

Authors:  M D Reed; R M Kliegman; T S Yamashita; C M Myers; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 6.  Pharmacokinetics in children.

Authors:  P A Routledge
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

7.  PRISM III: an updated Pediatric Risk of Mortality score.

Authors:  M M Pollack; K M Patel; U E Ruttimann
Journal:  Crit Care Med       Date:  1996-05       Impact factor: 7.598

Review 8.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

9.  Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis.

Authors:  G Claesson; M Eriksson; J D Rogers
Journal:  Pharmacol Toxicol       Date:  1992-08

Review 10.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803
View more
  13 in total

1.  Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

Authors:  J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf
Journal:  Br J Clin Pharmacol       Date:  2016-04-01       Impact factor: 4.335

Review 2.  Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

Authors:  Christopher M Rubino; John S Bradley
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

4.  Impact of Real-Time Therapeutic Drug Monitoring on the Prescription of Antibiotics in Burn Patients Requiring Admission to the Intensive Care Unit.

Authors:  P Voirol; Y-A Que; A Fournier; P Eggimann; O Pantet; J L Pagani; E Dupuis-Lozeron; A Pannatier; F Sadeghipour
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

6.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

7.  Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.

Authors:  F Lamoth; T Buclin; C Csajka; A Pascual; T Calandra; O Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

Review 8.  Year in review 2010: Critical Care--Infection.

Authors:  Leonardo Pagani; Arash Afshari; Stephan Harbarth
Journal:  Crit Care       Date:  2011-12-05       Impact factor: 9.097

9.  Pharmacokinetic/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study.

Authors:  B Abhilash; Chakra Dhar Tripathi; Anoop Raj Gogia; Girish Gulab Meshram; Manu Kumar; B Suraj
Journal:  Indian J Crit Care Med       Date:  2015-10

10.  Dosing Recommendations for Pediatric Patients With Renal Impairment.

Authors:  Amer Al-Khouja; Kyunghun Park; Daijha J C Anderson; Caitlyn Young; Jian Wang; Shiew Mei Huang; Mona Khurana; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2020-06-15       Impact factor: 3.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.